Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27142146 | 0.77 | PDGFRB (0.48) | ERN1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL27150529 | 0.74 | KDM4E (0.37) | ERN1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL22326645 | 0.72 | TET2 (0.38) | GRM5 | |
| SCHEMBL22326646 | 0.72 | CYP1A2 (0.38) | ALDH1A1MEN1KMT2AKDM4EPDE10A | |
| SCHEMBL31378742 | 0.72 | MAP4K4 (0.32) | ALDH1A1MEN1KMT2AKDM4EGRM5 | |
| SCHEMBL15941521 | 0.71 | PDGFRB (0.47) | ALDH1A1L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL15941400 | 0.71 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL15941604 | 0.70 | PDGFRB (0.42) | ALDH1A1L3MBTL1KDM4EPOLBPDE10A | |
| SCHEMBL23872148 | 0.70 | HCAR2 (0.46) | ALDH1A1MEN1KMT2AKDM4EPOLB | |
| SCHEMBL23858504 | 0.69 | CYP2C9 (0.46) | ALDH1A1L3MBTL1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | ERN1 4095/4885ALDH1A1 252/4885L3MBTL1 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.